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ABSTRACT
Idiopathic inflammatory myopathies (IIMs) encompass 
a heterogeneous group of rare autoimmune diseases 
characterised by muscle weakness and inflammation, 
but in antisynthetase syndrome arthritis and 
interstitial lung disease are more frequent and often 
inaugurate the disease. Clinical practice guidelines 
(CPGs) have been proposed for IIMs, but they are 
sparse and heterogeneous. This work aimed at 
identifying: i) current available CPGs for IIMs, ii) 
patients’ and clinicians’ unmet needs not covered by 
CPGs. It has been performed in the framework of the 
European Reference Network on rare and complex 
connective tissue and musculoskeletal diseases 
(ReCONNET), a network of centre of expertise and 
patients funded by the European Union’s Health 
Programme. Fourteen original CPGs were identified, 
notably recommending that: i) extra-muscular 
involvements should be assessed; ii) corticosteroids 
and methotrexate or azathioprine are first-line 
therapies of IIMs. iii) IVIG is a treatment of resistant-
DM that may be also used in other resistant-IIMs; iv) 
physical therapy and sun protection (in DM patients) 
are part of the treatment; v) tumour screening for 
patients with DM include imaging of chest, abdomen, 
pelvis and breast (in woman) along with colonoscopy 
(in patients over 50 years); vi) disease activity and 
damages should be monitor using standardised 
and validated tools. Yet, only half of these CPGs 
were evidence-based. Crucial unmet needs were 
identified both by patients and clinicians. In 
particular, there was a lack of large multidisciplinary 
working group and of patients’ preferences. 
The following fields were not or inappropriately 
targeted: diagnosis; management of extra-muscular 
involvements other than skin; co-morbidities and 
severe manifestations.
INTRODUCTION
Idiopathic inflammatory myopathies (IIMs) 
encompass a heterogeneous group of rare 
autoimmune diseases showing a large degree 
of overlap1 but also some peculiarities and 
differences, in particular in the setting of anti-
synthetase syndrome (ASSD).2 If IIMs affect 
adults and children, ASSD is generally an adult-
onset condition,3 with only few cases reported 
in paediatric age.4 IIMs are generally character-
ised by the occurrence of muscle weakness and 
inflammation, but in ASSD, arthritis and inter-
stitial lung disease (ILD) are more frequently 
Key messages
What is already known about this subject?
 ► Clinical practice guidelines (CPGs) have been pro-
posed for idiopathic inflammatory myopathies (IIMs) 
but no review of “what we have” and patients’ as 
well as clinicians’ unmet needs has been performed 
so far.
What does this study add?
 ► Fourteen original CPGs were identified, covering 
important issues.Yet, only half of these CPGs were 
evidence-based. and crucial unmet needs were 
identified both by patients and clinicians.
How might this impact on clinical practice?
 ► Future CPGs should include multidisciplinary stake-
holders, together with patients, to address the 
identified unmet needs in myositis care, based on 
growing evidence in the field.
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observed and frequently represent the first manifestation of 
the disease.5 Skin can also be frequently affected by IIMs, 
with occurrence of lesions such as heliotrope rash, Gottron’s 
sign/papules, skin ulcers, V-sign, Shawl sign, Hiker’s feet 
and mechanic’s hands, with these two latter considered as 
typical ASSD findings.6 7 Additionally, IIMs are associated 
with cancer,8 the risk of which is increased up to 5.3-fold 
with respect to general population in males with dermato-
myositis (DM).9 Thus, physicians from different specialties 
are involved in the care (including diagnosis, treatment and 
monitoring) of these patients. Even if IIMs are potentially 
treatable diseases, currently, mortality is hardly fourfold 
increased with respect to general population10 and quality of 
life is decreased.11 Considering the large number of special-
ists potentially involved in the daily management of these 
patients, as well as the different therapeutic approaches 
available, it is important to homogenise the different 
approaches, in order to establish a common shared strategy. 
Clinical practice guidelines (CPGs) are systematically devel-
oped statements to assist practitioner and patient decisions 
about appropriate healthcare for specific clinical circum-
stances.12 13 CPGs have been proposed for IIMs, but they 
are sparse and not homogeneous. This work attended 
to identify currently available CPGs for IIMs, to provide a 
narrative review of their contents and to identify patients’ 
and clinicians’ unmet needs. It has been performed in the 
framework of the European Reference Network on rare 
and complex connective tissue and musculoskeletal diseases 
(ERN ReCONNET), a Network of centre of expertise and 
patients funded by the European Union’s Health Program 
(reconnet. ern- net. eu).
METHODS
Objective and management of first work package of ERN 
ReCONNET
The aim of the first work package of ERN ReCONNET 
was the identification of field of application of identified 
CPGs, looking for potential unmet needs.
Planning and evaluation of the work was driven by 
regular interaction between participants of the working 
group during meetings (European League Against Rheu-
matism (EULAR) Congress 2017, American College of 
Rheumatology (ACR) Congress 2017, ERN ReCONNET 
Meeting, Pisa, 4–6 February 2018), web conferences, elec-
tronic letters and ERN Collaborative Platform (https:// 
webgate. ec. europa. eu).
Systematic literature search
Between June 2017 and February 2018, we carried out 
a search in PUBMED and EMBASE based on controlled 
terms (MeSH and Emtree), keywords of the disease and 
publication type (CPGs). All published articles were 
reviewed in order to identify existing CPGs on diagnosis, 
monitoring and treatment of IIMs, according to the Insti-
tute of Medicine 2011 definition (clinical practice guide-
lines are statements that include recommendations intended to 
optimise patient care that are informed by a systematic review of 
evidence and an assessment of the benefits and harms of alterna-
tive care options).
The Disease Coordinators (DCs) (LC and AM) of the 
ERN ReCONNET for IIMs have assigned the work on 
CPGs to the Healthcare Providers involved. Moreover, 
in order to implement the list of guidelines provided by 
Medline and Embase search, the group performed also 
a hand search. A first screening of evidence-based medi-
cine guidelines (regardless its level) was performed on 
the basis of their title and abstract (systematic search and 
hand search). A discussion group was set for the effective 
inclusion and evaluation of the existing CPGs, in order to 
identify the unmet needs.
Here is the search strategy: Medline (Pubmed): (“poly-
myositis” [MeSH Terms] OR “polymyositis” [All Fields] 
OR “dermatomyositis” [MeSH Terms] OR “dermato-
myositis” [All Fields] OR “myositis” [MeSH Terms] OR 
“myositis” [All Fields] OR (“idiopathic” [All Fields] 
AND “inflammatory” [All Fields] AND “myopathies” 
[All Fields]) OR “idiopathic inflammatory myopathies” 
[All Fields]) AND (“Practice Guideline” [Publica-
tion Type] OR “Practice Guidelines As Topic” [MeSH 
Terms] OR Practice Guideline [Publication Type] OR 
“Practice Guideline” [Text Word] OR “Practice Guide-
lines” [Text Word] OR “Guideline” [Publication Type] 
OR “Guidelines As Topic” [MeSH Terms] OR Guide-
line [Publication Type] OR “Guideline” [Text Word] 
OR “Guidelines” [Text Word] OR “Consensus Develop-
ment Conference” [Publication Type] OR “Consensus 
Development Conferences As Topic” [MeSH Terms] 
OR “Consensus” [MeSH Terms] OR “Consensus” 
[Text Word] OR “Recommendation” [Text Word] OR 
“Recommendations” [Text Word] OR “Best Practice” 
[TextWord] OR “Best Practices” [TextWord]). Embase: 
(‘myositis’/exp OR ‘idiopathic inflammatory myopathy’ 
OR ‘inflammatory myopathy’ OR ‘muscle inflamma-
tion’ OR ‘myopathy, inflammatory’ OR ‘polymyositis’/
exp OR 'fibromyositis’ OR 'polymyositis’ OR 'dermato-
myositis’/exp OR ‘dermatomyositides’ OR ‘dermatomy-
ositis’ OR ‘polymyositis arthropathica’) AND (‘practice 
guideline’/exp OR ‘practice guideline’ OR ‘practice 
guidelines’/exp OR ‘practice guidelines’ OR ‘clinical 
practice guideline’/exp OR ‘clinical practice guide-
line’ OR ‘clinical practice guidelines’/exp OR ‘clinical 
practice guidelines’ OR ’clinical practice guidelines as 
topic’/exp OR ‘clinical practice guidelines as topic’ 
OR ‘guideline’/exp OR ‘guideline’ OR ‘guidelines’/
exp OR ‘guidelines’ OR ‘guidelines as topic’/exp OR 
‘guidelines as topic’ OR ‘consensus development’/exp 
OR ‘consensus development’ OR ‘consensus develop-
ment conference’/exp OR ‘consensus development 
conference’ OR ‘consensus development conferences’/
exp OR ‘consensus development conferences’ OR 
‘consensus development conferences as topic’/exp 
OR ‘consensus development conferences as topic’ OR 
‘consensus’/exp OR ‘consensus’ OR ‘recommenda-
tion’ OR ‘recommendations’) AND [embase]/lim NOT 
[medline]/lim.
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Inclusion criteria and CPGs identification
CPGs were included if12 13:
i. Their development was aimed at assisting practi-
tioners’ and patients’ decisions about appropriate 
healthcare for patients with IIMs and ASSD.
ii. They were based on a systematic review of evidence.
iii. They were written in English.
All papers identified during the literature search were 
screened for eligibility by two evaluators and by DCs based 
on title and abstract assessment. Only papers consid-
ered eligible by at least one evaluator were included. 
Papers selected after the first round were then further 
assessed in order to verify their actual status of CPGs. In 
case of disagreement in the decision, a further round of 
discussion involving participants has been performed, in 
order to uniform the evaluation reaching the 100% of 
consensus.
Physicians’ and patients’ unmet needs were delin-
eated by focus groups conducted during the ERN 
meeting followed by written exchange during the redac-
tion process of the present manuscript. Patients were a 
51-year-old woman with bachelor’s degree, a 45-year-old 
man with bachelor’s degree and a 39-year-old woman 
with higher level of education.
RESULTS: STATE OF THE ART ON CPGS
Identification of existing CPGs
The systematic literature search provided a total of 727 
citations. Title and abstract evaluation identified 98 
papers suitable for full-text upload and review. After full-
text revision, we identified 14 original papers published 
between 1996 and 201714–32 (figure 1).
In the following sections, these papers will be thus 
defined as CPGs for practical purpose.
This is the first review providing an overview of 
currently available CPGs for IIMs whose characteristics 
and contents are resumed below and in tables 1 and 2.
CPGS CHARACTERISTICS
CPGs were written (first and/or last authors) by rheuma-
tologists (n=3), neurologists (n=7), dermatologists (n=3) 
and pulmonologists (n=1). In four CPGs, co-workers 
from different specialties than main authors were also 
involved. No CPGs involved clinicians from more than 
two different specialties. No CPGs involved patients.
Five CPGs were dedicated to IIMs, while nine covered a 
broader spectrum of diseases (including IIMs).
Nine CPGs targeted IIMs as a whole (juvenile and 
adult) although in four of the latter,14–16 23 authors did 
not state whether the recommendation applied to adult 
and/or juvenile IM. One paper targeted specifically juve-
nile IIMs and four specifically adults IIMs.
The majority of CPGs (n=13) focused on therapeutic 
questions including overall treatment, use of intrave-
nous globulin, management of lung and cutaneous 
disease. Others addressed disease measurements (tools 
for clinical assessment and improvement definition), 
associated conditions (cancer, pregnancy) and overall 
management. In seven CPGs, evidence was systematically 
searched and discussed (evidence-based CPGs). In the 
others, the method for evidence search was not provided 
(‘eminence-based’ CPGs). There were no specific recom-
mendations focusing on ASSD.
CPGS CONTENT
The covered points are as follows. (1) Global manage-
ment of juvenile dermatomyositis (DM), the most 
frequent IIMs in children,20 and of IIMs in general.19 23 31 
(2) The role of physical therapy in IIMs, focusing on the 
evaluation of disease-specific quality indicators, outcome 
measures and guidelines. The establishment of a physical 
rehabilitation path, in association to the pharmacolog-
ical treatments, is crucial to obtain the best improvement 
possible in these patients.15 (3) Screening of cancer, one 
of the leading causes of death in IIMs.32 (4) Use of intra-
venous immunoglobulin (IVIG), an expensive treatment 
that should be reserved only to specific clinical condi-
tions.14 16 17 21 29 (5) Cutaneous manifestations which are 
debilitating complications of various IIMs,22 in particular 
in juvenile forms.20 (6) ILD-related treatment,28 the main 
impacting prognostic factor in IIMs in general and in 
ASSD in particular. (7) Pregnancy planning and manage-
ment, in a field in which juvenile forms are common 
and young people in childbearing age can be affected by 
these diseases.18
Recommendations of available CPGs are presented 
in table 2 and notably stated that: (1) extramuscular 
involvements should be assessed; (2) corticosteroids and 
methotrexate or azathioprine are first-line therapies of 
IIMs; (3) IVIG is a treatment of resistant-DM that may be 
also used in other resistant-IIMs; (4) physical therapy and 
sun protection (in patients with DM) are part of the treat-
ment; (5) tumour screening for patients with DM include 
imaging of chest, abdomen, pelvis and breast (in woman) 
along with colonoscopy (in patients over 50 years); (6) 
Connective tissue diseases
Figure 1 Flow chart constructed from Pubmed, Embase 
and national databases. CPGs, clinical practice guidelines.
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disease activity and damages should be monitored using 
standardised and validated tools.
UNMET NEEDS
CPGs that are currently available do not cover the entire 
spectrum of IIMs needs. From the clinical point of view, 
we think that the identification of uncovered areas could 
be useful for the establishment of additional CPGs. From 
the scientific point of view, by considering that CPGs are 
recommendations based on scientific evidences, some of 
the unmet needs could indicate areas that deserve future 
research. Finally, it will be important to critically review 
the content of existing CPGs, in order to identify their 
strength and weakness, looking to their improvement, as 
planned in the next ReCONNET work packages.
Clinicians’ unmet needs
Even if several issues have been addressed, other relevant 
points are currently not or ineffectively targeted by CPGs 
IIMs that can be summarised as follows (table 3):
Unmet needs related to the stakeholders of CPGs development
 ► The lack of large multidisciplinary working group is 
the first transversal and crucial problem of available 
CPGs. Indeed, considering that patients with IIMs 
have multiorgan involvement with different manifes-
tations prevalence and severity levels, CPG for their 
optimal management cannot be developed without a 
larger number of different organ specialists as stake-
holders. In this regard, a collaboration of ReCONNET 
with other ERNs concern by IIMs (EURO-NMD and 
ERN LUNG) has been planned.
 ► Second, as IIMs are chronic diseases, patients’ 
perspective is mandatory for the improvement of daily 
quality of care. This issue will be overcome by initia-
tives notably started by the OMERACT (independent 
initiative of international health professionals inter-
ested in outcome measures in rheumatology).33
Unmet needs related to scope and target of the CPGs
 ► No CPGs are currently available for diagnosis. 
Early intervention may be associated with a better 
outcome34 but treatment is often delayed or not 
appropriated, because IIMs can be misdiagnosed as 
numerous other conditions including non-inflamma-
tory myopathies34 and other inflammatory diseases 
(such as rheumatoid arthritis35 or ILDs with autoim-
mune features36). On the other hand, mimickers of 
treatable IIMs include numerous non-inflammatory 
myopathies and inclusion body myositis.37 Although 
being an important milestone in the field, the recently 
published EULAR/ACR IIMs classification criteria 
did not match the definition of CPGs and were thus 
not included in this review. Yet, even considering 
RMD Open
Table 1 CPGs general characteristics
Author Date Target
Main authors 
specialty
Other specialty 
involved Based on Scope
Drake et al19 1996 IIMs as a whole Dermatology None Evidence
(grade C–D)
Treatment (overall)
Bril et al16 1999 IIMs as a whole Neurology None Eminence Treatment (IVIG)
Doria et al18 2004 Adult IIMs Rheumatology Neurology Eminence Pregnancy
Feasby et al21 2007 IIMs as a whole Neurology None Evidence
(grade B–D)
Treatment (IVIG)
Alexanderson et 
al15
2007 IIMs as a whole Rheumatology Physical therapy Eminence Disease measurement (tools)
Donofrio et al17 2009 Adult IIMs Neurology None Evidence
(grade B–D)
Treatment (IVIG)
Hengstman et al23 2009 IIMs as a whole Neurology None Eminence Treatment (overall)
Titulaer et al32 2011 IIMs as a whole Neurology None Evidence
(grade C–D)
Tumour screening
Patwa et al29 2012 Adult IIMs Neurology None Evidence
(grade B–D)
Treatment (IVIG)
Sunderkotter et 
al31
2016 IIMs as a whole Neurology Dermatologist Eminence General management
Enk et al14 2016 IIMs as a whole Dermatology None Eminence Treatment (IVIG)
Fujimoto et al22 2016 IIMs as a whole Dermatology None Evidence
(grade C–D)
Treatment (skin disease)
Morrisset et al28 2016 Adult IIMs Pneumology None Eminence Lung disease
Enders et al20 2017 Juvenile IIMs Rheumatology None Evidence
(grade B–D)
General management
Evidence was graded according to Grading of Recommendations Assessment, Development and Evaluation Working Group 2007 (http://www.
gradeworkinggroup.org/)
CPG: clinical practice guideline;IIM: idiopathic inflammatory myopathy; IVIG: intravenous immunoglobulin;
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Table 2 Scope and key recommendations of available CPGs for IIMs
Scope
First author, date of 
publication (ref) Key recommendations of the CPG
General management Sunderkotter, 201631
 ► All patients with IIMs should undergo a pulmonary function test and—in case of 
pathological findings—further pulmonology workup.
 ► Tumour screening in DM with anti-TIF1-γ include 18-fluoro-deoxyglucose-positron 
emission tomography/CT or CT of the thorax and abdomen in combination with a 
gynaecological/urological examination is recommended (no strategy is provided in 
other case by the CPG).
 ► Treatment of IIMs includes:
 – CS (intravenous if severe, oral if not).
 – AZA (for adult) and MTX (for children) when: (1) severe IIMs, (2) impossibility to 
reduce CS dosage below the ‘Cushing threshold’ after 3 months.
 – IVIG is recommended in patients unresponsive to CS+AZA.
 – Non-pharmacological measures: regular physical therapy, sun protection (for 
patients with DM).
Enders, 201720
 ► All children with suspected IIMs should be referred to a specialised centre. High-risk 
patients (as defined in the CPG) need immediate/urgent referral.
 ► Assessment of organ involvement (muscle, skin, lung, heart), calcinosis and 
antibodies (see CPG for details) is recommended for all children with IIMs.
 ► Disease activity, damages and health status should be monitored in a standardised 
way.
 ► Juvenile IIMs treatment includes:
 – Sun protection, exercise programme.
 – First line: high-dose CS and MTX.
 – If failure (considered within the first 12 weeks): topical TACRO/ CS (if localised 
skin disease), CsA or MMF (if intolerance to MTX), IVIG as adjunct or RTX as 
adjunct or CYC or antitumour necrosis factor therapies (if resistance).
Treatment (overall) Drake, 199619
 ► Non-pharmacological treatments of IIMs include physical therapy, photoprotection 
and adequate nutrition.
 ► Pharmacological treatments of IIMs include CS (topical and systemic); antimalarial 
and CS-sparing agents (no limitative list provided in the CPG).
 ► Calcinosis treatments include medical (diphosphonates, aluminium hydroxide, 
probenecid, colchicine and low-dose warfarin) and surgical management.
Hengstman, 200923  ► First line of IIMs is prednisone (1 mg/kg) and AZA or MTX.
 ► Second line, in case of severe pulmonary involvement, is CsA or TACRO or CYC.
 ► Second line, in case of no severe pulmonary involvement, is IVIG.
 ► Third line is RTX or TACRO or MMF or CsA or CYC.
Treatment (IVIG) Bril, 199916  ► IVIG is favourably recommended for the treatment of DM and recommended as a last 
resort for the other IIMs.
Feasby, 200721  ► IVIG is recommended as an adjunctive treatment for DM who did not adequately 
respond to other immunosuppressant medications (such as CS, MTX or AZA).
 ► IVIG may be considered as an adjunctive treatment option for PM who failed to 
respond to first-line therapies.
 ► IVIG is not recommended for IBM.
Donofrio, 200917  ► IVIG therapy is recommended as add-on treatment in refractory IIMs.
 ► IVIG is not recommended for IBM.
Patwa, 201229  ► IVIG may be considered for the treatment of non-responsive adult DM.
 ► Evidence is insufficient to support or refute the use of IVIG in treating IBM and PM.
Enk, 201614 Severe forms of DM, PM and IBM are considered by the authors as indication of IVIG, 
as first-line treatment (in fulminant course, severe myolysis or paralysis) or second-line 
treatment (in other cases), with continuation of immunosuppressive therapy.
Pregnancy Doria, 200418
 ► Patients with IIMs should be correctly informed on the risk of becoming pregnant.
 ► Pregnancies should be planned when IIMs is in remission
 ► Patients with IIMs should be regularly monitored during gestation and postpartum by 
a multidisciplinary team.
 ► In the case of disease relapse, treatment has to be started as soon as possible.
 ► IIMs treatment in pregnant patients is: CS (1 mg/kg/day until thenormalisation of 
serum creatine kinase levels). If insufficient response: CsA, AZA, plasma exchange or 
IVIG.
Continued
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these classification criteria,38 lung, joint and skin 
(other than DM rash) involvements are not taken 
into account,39 which is an issue especially for diag-
nosis of ASSD, as previously suggested by the Amer-
ican, European NEtwork of Antisynthetase Syndrome 
collaborative group.2 36 39–41 This unmet need will be 
fixed in next year thanks to CLASS project addressed 
to the establishment of next EULAR/ACR classifica-
tion criteria of ASSD.
 ► Management of extramuscular organ involvement 
other than skin is not appropriately targeted by 
current available CPGs. Of note, four papers address 
this important point, but have not been included in 
this review as they are based on expert consensus 
and thus do not match criteria for CPGs.24–27 Lung 
disease, one of the most frequent manifestations of 
IIMs and major cause of death10 is only addressed by 
one CPG.28 No CPG currently address heart, joints 
RMD Open
Scope
First author, date of 
publication (ref) Key recommendations of the CPG
Disease measurement 
(tools)
Alexanderson, 200715
 ► Disease activity and disability should be measured at disease onset, at 3, 6 and 12 
months, and then at least once a year.
 ► Only valid and reliable clinical outcome measures should be used (such clinical 
outcome measures were not available at the time of the publication of the CPG).
Tumour screening Titulaer, 201132
 ► Patients with DM should have CT-thorax/abdomen, ultrasound of the pelvic region 
and mammography in women, ultrasound of testes in men under 50 years and 
colonoscopy in men and women over 50.
 ► If primary screening is negative, repeat screening after 3–6 months and screen every 
6 months up till 4 years.
Extramuscular 
involvement (skin)
Fujimoto, 201622
 ► For calcinosis in IIMs: low-dose warfarin, aluminium hydroxide gel, diltiazem 
hydrochloride, probenecid or bisphosphonate are recommended as an option. 
Surgical treatment is also recommended as an option.
 ► For panniculitis in IIMs: CS is recommended. If no response, immunosuppressants 
such as CsA, MTX and AZA are recommended as an option.
Extramuscular 
involvement (lung)
Morrisset, 201628*  ► In acute or severe IIMs–ILD: high-dose steroids+CYC or RTX or CsA or TACRO is 
recommended.
 ► In chronic or mild to moderate IIMs–ILD: steroids+MMF or AZA is recommended.
 ► In case of failure: it is recommended to switch agent or consider combination of 
agents, or consider IVIG or consider transplantation referral.
AZA, azathioprine; CPGs, clinical practice guidelines; CS, corticosteriod; CYC, cyclophosphamide; CsA, ciclosporin A; DM, dermatomyositis; 
IBM, inclusion body myositis; IIM: idiopathic inflammatory myopathy; ILD: interstitial lung disease; IVIG, intravenous immunoglobulin; MMF, 
mycophenolate mofetil; MTX, methotrexate; PM, polymyositis; RTX, rituximab; TACRO, tacrolimus.
Table 2 Continued
Table 3 Synthesis of the physicians’ unmet needs
Unmet need related with Unmet needs Description
Stakeholders Patients’ preference None of the CPGs are based on patients preference.
Multidisciplinary working group None of the CPGs involved >2 different specialities.
CPGs scope and targets Diagnosis None of the CPGs provide a integrated strategy for diagnosis.
Extramuscular involvement
(other than skin)
Only one eminence-based CPG cover diagnosis and 
management of ILD.
No CPG specifically address management of heart, joints and 
gastroenterological manifestations.
Management by subgroups of IIMs None of the CPG is personalised by subgroup of inflammatory 
myopathies below than DM versus other IIMs.
Activity and damage assessment Only one eminence-based CPG specifically addresses disease 
activity and damages assessment.
Life or organ-function threatening 
complications
None of the CPG cover management of life or organ-function 
threatening complications.
Comorbidities None of the CPG cover comorbidities prevention, diagnosis and 
treatment.
Transition management None of the CPG targets transition management.
CPGs, clinical practice guidelines; DM, dermatomyositis; IIM: idiopathic inflammatory myopathy; ILD: interstitial lung disease.
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and gastroenterological manifestations, which are yet 
source of handicap and/or increased mortality.42–44
 ► IIMs are a heterogeneous group of diseases. The 
clinical manifestations, autoantibody proﬁle and 
muscle histology can be used to distinguish patient 
subgroups (extending their spectrum far beyond the 
subdivision between DM and other IIMs) with fairly 
homogeneous patterns of complications, treatment 
responses and outcomes. Yet, none of the CPGs iden-
tified in this review were specifically dedicated to one 
of these subgroups.
 ► Accurate monitoring of muscle inflammatory activity 
and damages are mandatory in order to meet the 
subtle threshold point between undertreatment and 
overtreatment. This challenge has been taken up by 
only one CPG. The recently published EULAR/ACR 
criteria for clinical response in adult and juvenile 
IIMs45 46 is an important step in this field. Yet, they 
were not included in this review because they did not 
match the definition of CPGs.
 ► Patients with IIMs may face life or organ-function 
threatening complications such as severe rapidly 
progressive ILD, myocarditis, pneumomediastinum, 
pulmonary hypertension, respiratory failure, prone 
position complication due to severe muscle weak-
ness dysphagia and ischaemic ulcerative colitis. These 
situations require peculiarly prompt diagnosis and 
management. Yet, no CPG currently cover these 
points.
 ► Side-effects of IIMs treatments and comorbidi-
ties (such as infections, osteoporosis, cardiovas-
cular events and high-risk pregnancy) are major 
causes of morbidity and mortality in patients with 
IIM.10 47 Prevention and management of these asso-
ciated conditions are currently not or only insuffi-
ciently targeted by CPGs.
 ► Transition management. IIMs encompass all ages with 
different disease phenotypes and different patients’ 
needs, in particular in the transition period. Patients’ 
approach of adult and paediatric clinicians is gener-
ally different, and this may be an additional serious 
problem to be considered.
Patients’ unmet needs
This paragraph intends to highlight the unmet needs of 
the IIMs European community. The content of this para-
graph has been carefully but hardly realised collecting 
the voices and the points of view of the patients affected 
by the disease. The rarity of the disease and the scar-
city of patient organisations made this work harder 
than expected. IIMs spectrum disorders encompass a 
large number of conditions with a very heterogeneous 
range of manifestations, not limited to muscle involve-
ment. On this basis, it is evident that patients’ needs 
are very different and deeply influenced by disease 
presentation pattern. Furthermore, also the diagnosis 
is not always easy to reach and this adds further uncer-
tainty to patients, with a large number of doubts about 
the carried disease: ‘I do not understand what I have?’, 
‘What is happening to me?’, ‘What should I expect 
from the future?’. Even if crucial, these questions have 
not always an answer in IIMs or, even worse, they have 
different answers according to the different referring 
specialist. Patients experience a lack of harmonisation 
in the medical approach and a scarce involvement in 
developing a common path. Being the diseases so heter-
ogeneous, each patient would bring its own experiences 
and suggestions adding further useful information and 
improving the care of these conditions. Unfortunately, 
only few clinicians are aware that patients need more 
direct support and attention: a continuous process of 
discussion and dialogue with physicians could be surely 
relevant to this purpose. Furthermore, patients refer 
that they need more personalised assistance from the 
national health systems, in term of social demands 
and attention. The lack of harmonisation of assistance 
creates differences in the European Countries and ERN 
ReCONNET is perceived to possibly fill this gap.
CONCLUSIONS
We identified the currently IIMs available CPGs, 
showing a large area of unmet needs. A further effort 
is necessary and it has been planned by the ERN 
ReCONNET in order to evaluate the intrinsic validity 
and applicability of available recommendations. The 
standardisation and sharing of CPGs, from diagnosis to 
treatment, are crucial to really improve the prognosis 
of these patients. We need therefore to work intensively 
together with patients focusing on the global improve-
ment of their daily life that represents a shared objec-
tive of patients and clinicians. We propose that future 
CPGs should include multidisciplinary stakeholders, 
together with patients, to address the identified unmet 
needs in myositis care, based on growing evidences.
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